Hyundai Bioscience Co., Ltd. (048410.KQ)
- Previous Close
10,510.00 - Open
10,580.00 - Bid 11,290.00 x --
- Ask 11,310.00 x --
- Day's Range
10,500.00 - 11,800.00 - 52 Week Range
9,320.00 - 22,700.00 - Volume
826,714 - Avg. Volume
210,693 - Market Cap (intraday)
542.619B - Beta (5Y Monthly) 1.06
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Aug 12, 2025 - Aug 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.
www.hyundaibioscience.comRecent News: 048410.KQ
View MorePerformance Overview: 048410.KQ
Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 048410.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 048410.KQ
View MoreValuation Measures
Market Cap
504.68B
Enterprise Value
527.62B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
47.13
Price/Book (mrq)
4.29
Enterprise Value/Revenue
49.27
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-46.04%
Return on Assets (ttm)
0.82%
Return on Equity (ttm)
-16.36%
Revenue (ttm)
15.05B
Net Income Avi to Common (ttm)
-6.93B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
3.66B
Total Debt/Equity (mrq)
67.43%
Levered Free Cash Flow (ttm)
-2.61B